Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Beam Therapeutics

Twist Bioscience Corp

Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.

3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers

Two months after my last bullish note on Crispr Therapeutics, predicting a bull run, the share price has barely budged. I find this surprising. Crispr and partner Vertex have now submitted their biologics license application to the FDA for approval of Sickle Cell Disease therapy.

Crispr Therapeutics: Upside Likely Coming Now That Exa-Cel Is With FDA

CRISPR Therapeutics is on the precipice of having its first FDA-approved therapy. The upstart biotech company is also working on a range of other potential therapies.

Is It Too Late to Buy CRISPR Stock?

Its gene-editing therapies could be game changers that revolutionize healthcare. If exa-cel is approved, it would serve as a functional cure for two challenging diseases.

Why CRISPR Therapeutics Just Became an Even Better Buy

Axsome Therapeutics

Intellia Therapeutics

Investors have shown keen interest in biotech after Johnson & Johnson's (NYSE: JNJ ) impressive earnings beat that topped Wall Street's expectations. The earnings beat reignited enthusiasm for biotech stocks, prompting investors to search for the next big players.

3 Biotech Stocks to Watch After Johnson & Johnson's Earnings Beat

NextEra Energy

Sometimes stocks go on sale, and it's up to you to decide whether to bite. CRISPR Therapeutics is on the verge of what could be its first major success.

Buy the Dip: 2 Top Stocks to Snatch Up Now

Eli Lilly

Axsome Therapeutics has several major milestones around the corner. CRISPR Therapeutics could soon win approvals for its first product.

3 Stocks With Huge Catalysts on the Way

Alphabet

Alphabet continues to explore new projects in addition to its core Google Search and YouTube segments. CRISPR Therapeutics is on the cusp of an approved gene-editing therapy that could be a game changer.

2 Growth Stocks That Could Keep Growing for Decades

Sana Biotechnology

Investors may want to keep an eye on the biotech boom and these top biotech stocks to watch. For one, the sector is still one of the safest, most recession-proof investments around.

The Top 3 Biotech Stocks to Watch in 2023

Legend Biotech

Madrigal Pharmaceuticals

Vaxcyte

Revolution Medicines

Ventyx Biosciences

Western Alliance Bancorporation

Where is the current bull market? All indications would be that it's in biotech!

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names

CRISPR Therapeutics stock has been surging ever since a U.S. drug-pricing group issued a favorable price point for its experimental therapy late last week. Today, the biotech's stock got another boost from Merck's premium-laden buyout of Prometheus Biosciences.

Why CRISPR Therapeutics Stock Is Marching Higher Today

Axsome last year launched two products that could bring in revenue of more than $1 billion each. CRISPR Therapeutics recently completed regulatory requests for its first potential product.

Better Growth Stock: Axsome vs. CRISPR Therapeutics

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock?

ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17th- 20th, 2023.

CRISPR Therapeutics to Participate in Needham's 22nd Annual Healthcare Conference

Delta Air Lines

Marathon Digital Holdings

Stocks are bouncing in the wake of the latest encouraging inflation reading.

3 Stocks Making Outsized Moves Today

Shares of Crispr Therapeutics (NASDAQ: CRSP ) stock are up by about 15% today following continued purchases by Cathie Wood's ARK Invest and an initiation of coverage from Cantor Fitzgerald's Olivia Brayer. Yesterday, Wood purchased a total of 56,492 shares of CRSP stock through the ARK Innovation ETF (NYSEMKT: ARKK ) and the ARK Genomic Revolution ETF (BATS: ARKG ).

Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock

Editas Medicine

Against the backdrop of a solid day on Wall Street, CRISPR Therapeutics (NASDAQ: CRSP ) distinguished itself, popping up nearly 16%. The catalyst appears to center on CRISPR's single-dose therapy for sickle cell disease ( SCD ), which it's developing with Vertex Pharmaceuticals (NASDAQ: VRTX ).

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?

CRISPR and Vertex Pharmaceuticals are jointly developing a gene-editing therapy to treat sickle cell disease and tranfusion-dependent beta thalassemia. The therapy is in Phase 3 trials and the companies have submitted their biologics license applications to the FDA.

Why Shares of CRISPR Therapeutics Jumped Thursday

Vertex Pharmaceuticals

Vertex Pharmaceuticals has a relatively safe top line, and more growth on the way. CRISPR Therapeutics is on track to start realizing revenue growth like wild.

2 Nasdaq Growth Stocks That Are Screaming Buys in April

Axsome launched its first products last year -- and others may be on the horizon. CRISPR recently completed regulatory submissions for a blood disorder candidate with blockbuster potential.

These Up-and-Coming Stocks Are Screaming Buys Right Now

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 105.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 105.26%: Read This Before Placing a Bet

ImmunoGen

Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.

Could This Move Make Vertex's Next Blockbuster Even Bigger?

CRISPR shares have declined quite a bit from a high a few years ago. But potential good news may be baked into the current price.

CRISPR Stock: Bull vs. Bear

Certara

Incyte

Morphosys AG - ADR

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

bluebird bio

CRISPR Therapeutics and Bluebird Bio will soon likely compete for market share. CRISPR has plenty of money and a collaborator with deep pockets.

News for CRISPR Therapeutics Stock (CRSP)